Market closed

ALX Oncology/$ALXO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About ALX Oncology

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Ticker

$ALXO
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
South San Francisco, United States

Employees

89
Website
www.alxoncology.com

ALX Oncology Metrics

BasicAdvanced
$89M
-
-$2.97
1.04
-

$89M

1.04

$17.83

$1.19

1.2M

4.821

4.631

11.324

12.688

-93.11%

-49.24%

-98.94%

0.65

0.65

-0.662

-16.85%

16.81%

What the Analysts think about ALX Oncology

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.

ALX Oncology Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALX Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ALX Oncology News

AllArticlesVideos
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewsWire·4 weeks ago
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

GlobeNewsWire·2 months ago
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALXO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ALX Oncology stock?

ALX Oncology (ALXO) has a market cap of $89M as of January 15, 2025.

What is the P/E ratio for ALX Oncology stock?

The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of January 15, 2025.

Does ALX Oncology stock pay dividends?

No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next ALX Oncology dividend payment date?

ALX Oncology (ALXO) stock does not pay dividends to its shareholders.

What is the beta indicator for ALX Oncology?

ALX Oncology (ALXO) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.